Want to see DHR full AI Analyst Report?
Operating Income by Segment
Shows profit generated from each business unit, highlighting which segments drive earnings and where there might be challenges or opportunities for growth.Life Sciences operating income has materially downshifted from its pre‑2023 peaks and shows episodic volatility, including a mid‑2025 setback, suggesting structural instrument softness and one‑offs rather than steady recovery. By contrast, the newly visible Biotechnology line has become Danaher’s consistent earnings engine—matching management’s emphasis on bioprocessing consumables strength and sharply higher equipment orders—and helps offset Diagnostics’ China‑driven slump, which has since rebounded. Environmental disappears after 2023, signaling portfolio simplification, while 'Other' remains a steady, modest drag on corporate operating income.
Date | Other | Life Sciences | Diagnostics | Environmental | Biotechnology |
|---|---|---|---|---|---|
Jun 30, 2026 | -$86.00M | $244.00M | $416.00M | $0.00 | $556.00M |
Mar 31, 2026 | -$89.00M | $225.00M | $674.00M | $0.00 | $534.00M |
Dec 31, 2025 | -$87.00M | $336.00M | $713.00M | $0.00 | $540.00M |
Sep 30, 2025 | -$85.00M | $222.00M | $665.00M | $0.00 | $352.00M |
Jun 30, 2025 | -$86.00M | -$239.00M | $554.00M | $0.00 | $531.00M |
Mar 31, 2025 | -$86.00M | $201.00M | $718.00M | $0.00 | $441.00M |
Dec 31, 2024 | -$83.00M | $376.00M | $624.00M | $0.00 | $508.00M |
Sep 30, 2024 | -$82.00M | $35.00M | $615.00M | $0.00 | $390.00M |
Jun 30, 2024 | -$83.00M | $233.00M | $556.00M | $0.00 | $402.00M |
Mar 31, 2024 | -$78.00M | $235.00M | $830.00M | $0.00 | $325.00M |